Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:BVXVNASDAQ:ENTXNASDAQ:SNCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENTXEntera Bio$2.07-6.8%$1.63$0.52▼$3.35$59.62M1.7210,364 shs163,373 shsSNCASeneca Biopharma$6.35+7.3%$3.47$0.50▼$2.67$109.83M1.833.78 million shs457,607 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.11%-92.97%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-28.80%ENTXEntera Bio+8.29%-3.06%+40.51%+158.14%+179.25%SNCASeneca Biopharma+25.69%+42.31%+1,482.46%+1,056.02%+236.36%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio1.6024 of 5 stars3.53.00.00.03.30.00.0SNCASeneca BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AENTXEntera Bio3.00Buy$10.00383.09% UpsideSNCASeneca BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest BVXV, ENTX, ACOR, and SNCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AENTXEntera Bio$130K458.58N/AN/A$0.36 per share5.75SNCASeneca Biopharma$10K10,982.96N/AN/A$1.33 per share4.77Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)SNCASeneca Biopharma-$8.35MN/A0.00∞N/A-230.34%-122.20%-110.61%N/ALatest BVXV, ENTX, ACOR, and SNCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/ASNCASeneca BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BVXVBiondVax PharmaceuticalsN/A4.124.12ENTXEntera BioN/A10.3210.32SNCASeneca BiopharmaN/A14.9614.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BVXVBiondVax Pharmaceuticals11.83%ENTXEntera Bio14.11%SNCASeneca Biopharma5.24%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BVXVBiondVax Pharmaceuticals6.03%ENTXEntera Bio8.90%SNCASeneca Biopharma2.11%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableENTXEntera Bio1728.80 million26.24 millionOptionableSNCASeneca Biopharma717.30 millionN/ANot OptionableBVXV, ENTX, ACOR, and SNCA HeadlinesSourceHeadlineLeading BioSciences Inc, Seneca Biopharma, Inc. - M&A Call Transcriptgurufocus.com - March 2 at 1:09 AMLeading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call Transcriptgurufocus.com - March 2 at 1:09 AMSeneca Park Zoo announces death of Canada lynxdemocratandchronicle.com - January 6 at 1:18 PM4 Bedroom Home in Seneca Falls - $499,000auburnpub.com - December 19 at 8:57 AMSeneca Foods Corp Class Amorningstar.com - December 16 at 2:26 PMSeneca, Schuyler Thruway service areas reopen with upgraded facilitiesdemocratandchronicle.com - November 11 at 7:30 PMColin Walsh lost his starting QB job, now he's a defensive leader for Seneca footballcourierpostonline.com - November 10 at 3:23 PMSeneca Park Zoo welcomes new 2-year-old giraffe. See the photosdemocratandchronicle.com - October 26 at 6:52 PM‘The Show’ @ Shea’s Senecabuffalorising.com - June 15 at 10:49 PMDone Deal: Highmark Moving to Seneca Onebuffalorising.com - May 5 at 6:45 PMSeneca to transform decades-old Sport Centre into health and wellness complex infused with Indigenous design, sustainabilitytoronto.com - May 5 at 6:45 PMBetter Look: Seneca One Plansbuffalorising.com - May 4 at 3:25 AMWest Seneca West Senior High Schoolusnews.com - April 30 at 9:47 AMSeneca High Schoolusnews.com - April 19 at 3:53 PMFormer West Seneca police officer sentenced for stealing from retail storeswkbw.com - March 29 at 8:36 PMSt. Patrick's Day Music Fest in West Senecawkbw.com - March 20 at 8:40 PMSeneca County deputies: 9-year-old dies after car slides down embarkmentwhec.com - March 1 at 9:37 AM9-year-old girl dies in Seneca County crashdemocratandchronicle.com - March 1 at 9:37 AMWest Seneca man sentenced to prison for possession of child pornographywkbw.com - March 1 at 9:37 AMWest Seneca police locate missing 17-year-oldwkbw.com - February 26 at 10:14 AMHistorical society publishes book on Seneca Ray Stoddardnews10.com - February 23 at 11:35 PM'This is a tragedy': Giraffe dies after getting caught in enclosure gate at New York zoousatoday.com - February 16 at 2:06 PMIllinois State, Seneca Knight try to get home mojo working against Missouri Statepantagraph.com - January 12 at 10:34 PMSeneca football sports perfect 4-0 recordjoplinglobe.com - September 23 at 1:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Entera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Seneca BiopharmaNASDAQ:SNCASeneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.